Cargando…
Targeting NF-kappa B Signaling by Artesunate Restores Sensitivity of Castrate-Resistant Prostate Cancer Cells to Antiandrogens()()
Androgen deprivation therapy (ADT) is the most preferred treatment for men with metastatic prostate cancer (PCa). However, the disease eventually progresses and develops resistance to ADT in majority of the patients, leading to the emergence of metastatic castration-resistant prostate cancer (mCRPC)...
Autores principales: | Nunes, Jessica J., Pandey, Swaroop K., Yadav, Anjali, Goel, Sakshi, Ateeq, Bushra |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5358938/ https://www.ncbi.nlm.nih.gov/pubmed/28319807 http://dx.doi.org/10.1016/j.neo.2017.02.002 |
Ejemplares similares
-
Strategies to Re-Sensitize Castration-Resistant Prostate Cancer to Antiandrogen Therapy
por: Congregado Ruiz, Belén, et al.
Publicado: (2023) -
Resistance to Novel Antiandrogen Therapies in Metastatic
Castration-Resistant Prostate Cancer
por: Boudadi, Karim, et al.
Publicado: (2016) -
Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer
por: Rice, Meghan A., et al.
Publicado: (2019) -
Selective androgen receptor degrader (SARD) to overcome antiandrogen resistance in castration-resistant prostate cancer
por: Wu, Meng, et al.
Publicado: (2023) -
Androgen Receptor Variants Confer Castration Resistance in Prostate Cancer by Counteracting Antiandrogen-Induced Ferroptosis
por: Sun, Rui, et al.
Publicado: (2023)